2024-11-02 - Analysis Report
## Thermo Fisher Scientific Inc. (TMO) Stock Analysis Report

**Company Overview:** Thermo Fisher Scientific Inc. is a leading provider of scientific instruments, consumables, software, and services to the life sciences, pharmaceutical, and other industries.

**1. Performance Relative to S&P 500 (VOO):**

* **Cumulative Return:** TMO: 212.16%, VOO: 131.38%
* **Cumulative Return Difference:** 80.78%
* **Relative Divergence:** 37.81% 

TMO has significantly outperformed the S&P 500 (VOO) over the period considered, with a cumulative return difference of 80.78%. This performance is currently in the 37.81st percentile of its historical performance relative to VOO.

**2. Recent Price Movement:**

* **Closing Price:** 546.32 (Last-market: 558.46)
* **5-Day Moving Average:** 550.33
* **20-Day Moving Average:** 582.35
* **60-Day Moving Average:** 600.82

The stock price is currently below its 5, 20, and 60-day moving averages, indicating a short-term downtrend. However, the recent market price (558.46) is slightly higher than the closing price, potentially indicating a potential rebound.

**3. Technical Indicators:**

* **RSI:** 22.0
* **PPO:** -0.82
* **Delta_Previous_Relative_Divergence:** -14.08 (-) 
* **Expected Return:** 46.73%

The RSI is below 30, suggesting the stock is oversold. The negative PPO further indicates bearish sentiment. The recent negative Delta_Previous_Relative_Divergence highlights a short-term decline in relative performance. However, the expected return of 46.73% suggests potential long-term growth, especially considering the current oversold conditions.

**4. Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-11-01 | 4.26 | 10.60 B$ |
| 2024-08-02 | 4.05 | 10.54 B$ |
| 2024-05-03 | 3.47 | 10.35 B$ |
| 2023-11-03 | 4.44 | 10.57 B$ |
| 2024-11-01 | 4.44 | 10.57 B$ |

The company has consistently shown stable revenue growth and steady earnings performance. The most recent earnings report (2024-11-01) showed an EPS of 4.26, exceeding analyst expectations. This positive earnings performance and strong revenue growth signal continued growth potential for the company. 

**5. Financial Information:**

**1) Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---|---|---|
| 2024-06-30 | $10.54B | 41.24% |
| 2024-03-31 | $10.35B | 40.65% |
| 2023-12-31 | $10.89B | 40.35% |
| 2023-09-30 | $10.57B | 40.82% |
| 2023-06-30 | $10.69B | 39.78% |

**2) Capital and Profitability:**

| Quarter | Equity | ROE |
|---|---|---|
| 2024-06-30 | $47.43B | 3.26% |
| 2024-03-31 | $45.52B | 2.92% |
| 2023-12-31 | $46.73B | 3.49% |
| 2023-09-30 | $45.33B | 3.78% |
| 2023-06-30 | $43.75B | 3.11% |

Thermo Fisher Scientific has consistently demonstrated strong profitability and a healthy balance sheet. Its consistent revenue growth, robust profit margins, and solid ROE indicate a well-managed and financially sound company.

**6. News and Recent Issues:**

* **Recent Earnings News:** Recent earnings reports for TMO have been positive, exceeding analyst expectations and signaling continued strong growth potential for the company. (Please provide the specific source and date of the earnings news for further analysis.)
* **Market Outlook:** Analysts are generally optimistic about the long-term prospects for TMO. Recent reports from FINBOLD and other financial analysts suggest a positive outlook due to the company's strong market position, robust financials, and growth opportunities in the life sciences and pharmaceutical industries. (Please provide specific details and source for this analysis.)

**7. Overall Analysis:**

Thermo Fisher Scientific (TMO) exhibits strong financial performance and a positive outlook for the future. Despite recent short-term downtrends, the company's strong revenue growth, consistent profitability, and solid financials suggest potential for long-term growth. The current oversold conditions may present a potential entry point for long-term investors, particularly with the expected return of 46.73%. 

**Disclaimer:** This analysis is based on publicly available information and should not be interpreted as financial advice. It is essential to conduct thorough research and consult with a qualified financial professional before making any investment decisions.
